Belvedere Trading’s Kura Oncology KURA Stock Holding History

Belvedere Trading’s Portfolio KURA Stock Details KURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-505	Closed	-$6.27K	–	1217
2022 Q4	$6.27K	Buy	+505	New	+$7.34K	﹤0.01%	962

Other funds holding KURA

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Belvedere Trading's KURA Position: Q1 2023 in Review

Belvedere Trading sold out of Kura Oncology (KURA) in Q1 2023, closing a stake of 505 shares — an estimated $6.27K sold.

Belvedere Trading first reported a position in KURA in Q4 2022 and held it in 1 quarter. The position peaked at $6.27K in Q4 2022. 141 funds tracked by Wall St. Rank hold KURA as of Q1 2023.

Belvedere Trading reported no remaining Kura Oncology position as of Q1 2023 after selling out during the quarter.
Belvedere Trading sold 505 Kura Oncology shares in Q1 2023, an estimated $6.27K.
Belvedere Trading first reported a position in Kura Oncology in Q4 2022 and held it in 1 quarter.
Belvedere Trading's Kura Oncology position peaked at $6.27K in Q4 2022.
141 funds tracked by Wall St. Rank held Kura Oncology as of Q1 2023.

Based on Belvedere Trading's 13F filing for Q1 2023, filed 15 May 2023.